Advertisement
Loading...

Vivani Medical, Inc.

VANIWPNK
Healthcare
Medical - Devices
$0.01
$-0.01(-52.47%)
U.S. Market opens in 6h 36m
Advertisement

Vivani Medical, Inc. Fundamental Analysis

Vivani Medical, Inc. (VANIW) shows weak financial fundamentals with a PE ratio of -3.93, profit margin of 0.00%, and ROE of -2.64%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position2406.02%
PEG Ratio-0.60
Current Ratio3.18

Areas of Concern

ROE-2.64%
Operating Margin0.00%
We analyze VANIW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -305.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-305.1/100

We analyze VANIW's fundamental strength across five key dimensions:

Efficiency Score

Weak

VANIW struggles to generate sufficient returns from assets.

ROA > 10%
-63.96%

Valuation Score

Excellent

VANIW trades at attractive valuation levels.

PE < 25
-3.93
PEG Ratio < 2
-0.60

Growth Score

Weak

VANIW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

VANIW maintains a strong and stable balance sheet.

Debt/Equity < 1
0.96
Current Ratio > 1
3.18

Profitability Score

Weak

VANIW struggles to sustain strong margins.

ROE > 15%
-264.04%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is VANIW Expensive or Cheap?

P/E Ratio

VANIW trades at -3.93 times earnings. This suggests potential undervaluation.

-3.93

PEG Ratio

When adjusting for growth, VANIW's PEG of -0.60 indicates potential undervaluation.

-0.60

Price to Book

The market values Vivani Medical, Inc. at 5.58 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.58

EV/EBITDA

Enterprise value stands at -2.88 times EBITDA. This is generally considered low.

-2.88

How Well Does VANIW Make Money?

Net Profit Margin

For every $100 in sales, Vivani Medical, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-2.64 in profit for every $100 of shareholder equity.

-2.64%

ROA

Vivani Medical, Inc. generates $-63.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

-63.96%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.33 in free cash annually.

$-0.33

FCF Yield

VANIW converts -35.08% of its market value into free cash.

-35.08%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.93

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.60

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.58

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.96

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.18

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.64

vs 25 benchmark

ROA

Return on assets percentage

-0.64

vs 25 benchmark

ROCE

Return on capital employed

-0.78

vs 25 benchmark

How VANIW Stacks Against Its Sector Peers

MetricVANIW ValueSector AveragePerformance
P/E Ratio-3.9328.32 Better (Cheaper)
ROE-264.04%733.00% Weak
Net Margin0.00%-53055.00% (disorted) Weak
Debt/Equity0.960.38 Weak (High Leverage)
Current Ratio3.184.03 Strong Liquidity
ROA-63.96%-19488.00% (disorted) Weak

VANIW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Vivani Medical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ